Electronic Supplementary Material (ESI) for RSC Advances.

Supporting Information

An Innovative Strategy to Obtain Extraordinary Specificity in Immunofluorescent Labeling and Optical Super Resolution Imaging of Microtubules

Shenfei Zong, Chen Chen, Yizhi Zhang, Lang Li, Zhuyuan Wang, Yiping Cui**

Advanced Photonics Center, Southeast University, Nanjing 210096, Jiangsu, China

*cyp@seu.edu.cn; wangzy@seu.edu.cn



Figure S1. (a) Fluorescence spectrum of Secondary Antibody 1. The excitaion light is 633 nm. (b) Fluorescence spectrum of Secondary Antibody 2. The excitation light is 488 nm.



Figure S2. Z-stack CLSM images of HeLa cells permeabilized with 0.015% Triton X-100 for 2 min first. Secondary Antibody 1 was used. The Last picture shows a merged image of fluorescence and bright field images.



Figure S3. Z-stack CLSM images of HeLa cells permeabilized with 0.015% Triton X-100 for 2 min first. Secondary Antibody 2 was used. The Last picture shows a merged image of fluorescence and bright field images.



Figure S4. Z-stack CLSM images of HeLa cells labeled using Protocol 1. Secondary Antibody 2 was used.



Figure S5. Z-stack CLSM images of HeLa cells labeled using Protocol 3. Secondary Antibody 2 was used.



Figure S6. Z-stack CLSM images of HeLa cells labeled using Protocol 2. Secondary Antibody 2 was used.



Figure S7. Z-stack CLSM images of MRC-5 cells labeled using Protocol 1. Secondary Antibody 1 was used.



Figure S8. Z-stack CLSM images of MRC-5 cells labeled using Protocol 1. Secondary Antibody 2 was used.



Figure S9. Z-stack CLSM images of MRC-5 cells labeled using Protocol 2. Secondary Antibody 1 was used.



Figure S10. Z-stack CLSM images of MRC-5 cells labeled using Protocol 2. Secondary Antibody 2 was used.



Figure S11. Z-stack CLSM images of MRC-5 cells labeled using Protocol 3. Secondary Antibody 1 was used.



Figure S12. Z-stack CLSM images of MRC-5 cells labeled using Protocol 3. Secondary Antibody 2 was used.



Figure S13. Z-stack CLSM images of SKBR3 cells labeled using Protocol 1. Secondary Antibody 1 was used.



Figure S14. Z-stack CLSM images of SKBR3 cells labeled using Protocol 1. Secondary Antibody 2 was used.



Figure S15. Z-stack CLSM images of SKBR3 cells labeled using Protocol 2. Secondary Antibody 1 was used.



Figure S16. Z-stack CLSM images of SKBR3 cells labeled using Protocol 2. Secondary Antibody 2 was used.



Figure S17. Z-stack CLSM images of SKBR3 cells labeled using Protocol 3. Secondary Antibody 1 was used.



Figure S18. Z-stack CLSM images of SKBR3 cells labeled using Protocol 3. Secondary Antibody 2 was used.



Figure S19. PKH26 stained cells which are only fixed with PFA without membrane permeabilization by TX100.



Figure S20. SMLM imaging of HeLa cells prepared by Protocol 1 and Protocol 2. The dashed circles indicate microtubular junctions.